Previous 10 | Next 10 |
Quick Take Precision BioSciences ( DTIL ) intends to raise $126 million in an IPO of its common stock, per an amended registration statement . The company has created an advanced gene-editing platform for a variety of disease conditions and crop modification purposes. DTIL has promising...
Bristol-Myers Squibb (NYSE: BMY ) investor Starboard Value has just released a new presentation supporting its opposition to the company's planned $74B takeover of Celgene (NASDAQ: CELG ). Key points: More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news...
With New Year's celebrations barely winding down, 2019 started with a bang with the announcement of the largest ever U.S. pharmaceutical deal. The news of Bristol-Myers Squibb ( BMY ) acquiring Celgene ( CELG ) immediately caused BMY stock to drop over 13% from $52.02 to $45.12 while Celgene s...
The April 12 th vote for the $74 Billion Bristol-Myers Squibb ( BMY ) - Celgene ( CELG ) merger is fast approaching, and activist investors against the deal are calling shenanigans . Hedge Fund Starboard Value is leveling accusations of empty voting, which is when shares of a company are bou...
The board of OncoMed Pharmaceuticals (NASDAQ: OMED ) has declared a one-time special dividend to stockholders in the form of a contractual right to receive cash payments related to Celgene's (NASDAQ: CELG ) option on etigilimab. More news on: OncoMed Pharmaceuticals, Inc., Celgene Corpor...
March 14, 2019 Palm Beach, FL – March 14, 2019 – According to the Leukemia & Lymphoma Society, the world’s largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are an estimat...
Bristol-Myers Squibb ( BMY ) CEO Giovanni Caforio is showing tremendous commitment to the deal with Celgene ( CELG ) as he's touring all kinds of events. Today he's showing up at the Barclays healthcare conference . Yesterday, he said some remarkable things at the Cowen conference . I alread...
It may come down to the wire for Bristol-Myers ( BMY ) to get enough shareholder votes to move ahead with its proposed $74 billion takeover of biotech giant Celgene ( CELG ). But the deal is no sure thing, with opposition from some of Bristol's largest shareholders. An analysis of the option...
Celgene (NASDAQ: CELG ) reports that a Phase 3 clinical trial, Apact , evaluating the combination of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine versus gemcitabine alone in surgically resected pancreatic cancer failed to demonstr...
TECENTRIQ ® in Combination with ABRAXANE ® receives accelerated approval for people with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...